Clinical Study

Alector Study

Posted Date: May 29, 2020

  • Investigator: Russell Sawyer
  • Specialties:
  • Type of Study: Drug

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations inthe Progranulin Gene


Please Contact The Study Contact For Further Details On The Eligibility Criteria


Frontotemporal Dementia, Dementia, Heterozygous Mutation

For More Information:

Kayla Stallworth

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.